XOPENEX HFA (levalbuterol tartrate) by Lupin Ltd. is 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic amp). First approved in 2005.
Drug data last refreshed 23h ago · AI intelligence enriched 1mo ago
XOPENEX HFA is a metered-dose inhaler containing levalbuterol tartrate, the active (R)-enantiomer of albuterol, used to treat or prevent bronchospasm in patients with reversible obstructive airway disease. It works by stimulating beta-2 adrenergic receptors on airway smooth muscle, increasing cyclic AMP and triggering smooth muscle relaxation while inhibiting mast cell mediator release. Levalbuterol is a functional bronchodilator antagonist effective against all bronchoconstrictor challenges.
Product approaching loss of exclusivity with modest Medicare spending (~$141K in 2023) suggests a declining team footprint and shift toward generic transition support roles.
2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn,…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on XOPENEX HFA at Lupin Ltd.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
XOPENEX offers limited career upside due to LOE approaching and modest spending ($141K Part D); roles focus on defensive managed care strategy and generic transition management rather than growth initiatives. Professionals joining this product should expect restructuring and eventual transition to mature/generic portfolio management or reassignment to growth-stage franchises.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo